Evidence map›Paper›PMID 24727059›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2014

Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.

Jeane Chen, Alexander Y Sheu, Weiguo Li, Zhuoli Zhang, Dong-Hyun Kim, Robert J Lewandowski, Reed A Omary, Lonnie D Shea, Andrew C Larson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jeane ChenDepartment of Chemical & Biological Engineering, Northwestern University, Evanston, IL, USA; Department of Radiology, Northwestern University, Chicago, IL, USA.
Alexander Y SheuDepartment of Radiology, Northwestern University, Chicago, IL, USA.
Weiguo LiDepartment of Radiology, Northwestern University, Chicago, IL, USA.
Zhuoli ZhangDepartment of Radiology, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Dong-Hyun KimDepartment of Radiology, Northwestern University, Chicago, IL, USA.
Robert J LewandowskiDepartment of Radiology, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Reed A OmaryDepartment of Radiology, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA.
Lonnie D SheaDepartment of Chemical & Biological Engineering, Northwestern University, Evanston, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Andrew C LarsonDepartment of Radiology, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA; Department of Electrical Engineering and Computer Science, Evanston, IL, USA. Electronic address: a-larson@northwestern.edu.
Northwestern University · USEvanston Hospital · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Quantitative MRI-Guided Nanoembolization for Liver CancerR01CA159178 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LARSON, ANDREW CHRISTIAN, OMARY, REED A. · 2011 to 2015
$2.4M
MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver TumorsR01CA181658 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LARSON, ANDREW CHRISTIAN · 2015 to 2019
$2.1M
MRI of Iron-labeled Microsphere Biodistribution for Radioembolization DosimetryR01CA141047 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LARSON, ANDREW CHRISTIAN · 2010 to 2013
$1.2M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA060553NCI NIH HHS R01 CA141047NCI NIH HHS R01 CA159178NCI NIH HHS R01 CA181658
6 · The paper itself

Abstract

The multi-kinase inhibitor (MKI) sorafenib can be an effective palliative therapy for patients with hepatocellular carcinoma (HCC). However, patient tolerance is often poor due to common systemic side effects following oral administration. Local transcatheter delivery of sorafenib to liver tumors has the potential to reduce systemic toxicities while increasing the dose delivered to targeted tumors. We developed sorafenib-eluting PLG microspheres for delivery by intra-hepatic transcatheter infusion in an orthotropic rodent HCC model. The particles also encapsulated iron-oxide nanoparticles permitting magnetic resonance imaging (MRI) of intra-hepatic biodistributions. The PLG microspheres (diameter≈1μm) were loaded with 18.6% (w/w) sorafenib and 0.54% (w/w) ferrofluid and 65.2% of the sorafenib was released within 72h of media exposure. In vitro studies demonstrated significant reductions in HCC cell proliferation with increasing doses of the sorafenib-eluting microspheres, where the estimated IC50 was a 29μg/mL dose of microspheres. During in vivo studies, MRI permitted intra-procedural visualization of intra-hepatic microsphere delivery. At 72h after microsphere infusion, microvessel density was significantly reduced in tumors treated with the sorafenib-eluting microspheres compared to both sham control tumors (by 35%) and controls (by 30%). These PLG microspheres offer the potential to increase the efficacy of molecularly targeted MKI therapies while reducing systemic exposures via selective catheter-directed delivery to HCC.

Indexed as

MicrospheresAnimalsAntineoplastic AgentsCarcinoma, HepatocellularCatheterizationCell Line, TumorCell ProliferationDrug CarriersLiverLiver NeoplasmsMagnetic Resonance ImagingMaleNiacinamidePhenylurea CompoundsPolyglactin 910Protein Kinase InhibitorsAntineoplastic AgentsDrug CarriersNiacinamidePhenylurea CompoundsPolyglactin 910Protein Kinase InhibitorsSorafenibHepatocellular carcinomaMagnetic resonance imagingPoly(lactide-co-glycolide)Sorafenib

Identifiers

PMID24727059
PMCPMC4058431
OpenAlexW2004187455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.